Biologics for chronic inflammatory diseases, such as moderate to severe rheumatoid arthritis, were a true advance. With their advent, the provider's treatment plan for their patients was no longer just about managing symptoms, but about potentially putting the disease into clinical remission by inhibiting specifically targeted biochemical pathways of inflammation.2
Amgen has been at the forefront of innovator biologic medicines for inflammation for over 20 years. Now we have a pipeline that is rich in biosimilars that treat inflammation.